Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2019 - 2021)

Fulcrum Therapeutics (FULC) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1.7 million as the latest value for Q4 2021.

  • On a quarterly basis, Non-Current Deffered Revenue rose 1.88% to $1.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.7 million, a 1.88% increase, with the full-year FY2021 number at $1.7 million, up 1.88% from a year prior.
  • Non-Current Deffered Revenue was $1.7 million for Q4 2021 at Fulcrum Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $6.0 million in Q4 2019 to a low of $1.5 million in Q3 2019.
  • A 3-year average of $3.0 million and a median of $1.7 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 290.64% in 2020; the steepest drop was 72.57% in 2020.
  • Fulcrum Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2019, then plummeted by 72.57% to $1.6 million in 2020, then rose by 1.88% to $1.7 million in 2021.
  • Per Business Quant, the three most recent readings for FULC's Non-Current Deffered Revenue are $1.7 million (Q4 2021), $1.6 million (Q3 2021), and $1.7 million (Q2 2021).